Mannin Research Inc.

Mannin Research Inc. (Mannin), is a privately held, biotechnology company, founded in July, 2012. Focused on the discovery, development, and commercialization of first-in-class therapeutics for vascular diseases using the Tie2 mechanism of action. Mannin’s research program is led by Chief Scientific Officer, Dr. Susan E. Quaggin, Chief of Nephrology and Director of the Feinberg Institute at Northwestern University. With a strong intellectual property portfolio, a formal research partnership with Northwestern University, revenue generating research and development and licensing agreement with QBioMed (OTCQB: QBIO), Mannin is leading the development of a new class of compounds for a range of vascular diseases beginnin